Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...
-
Raleigh, NC, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Raleigh, NC— Premier destination for aesthetic excellence in Raleigh, Lyle Plastic Surgery and Aesthetics Center, is proud to unveil its latest...
-
Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea & Vomiting Induced by GLP-1 Receptor Agonist Semaglutide
-
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
-
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”)...
-
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
-
Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors